<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Petryk A</submitter><funding>NCATS NIH HHS</funding><funding>NCRR NIH HHS</funding><funding>NCI/NIDDK</funding><funding>NCI NIH HHS</funding><funding>Children&amp;apos;s Cancer Research Fund</funding><pagination>467-73</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3529966</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>60(3)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Childhood cancer survivors (CCS) are at risk for growth hormone (GH) deficiency. CCS are also at increased risk for early mortality from cardiovascular (CV) disease, but the association between GH levels and CV risk remains poorly understood. The goal of this study was to examine the cross-sectional association between stimulated GH levels and CV risk factors in CCS younger than 18 years.&lt;h4>Procedure&lt;/h4>A total of 276 CCS (147 males, 14.4 ± 2.6 years) ≥5 years after cancer diagnosis, and 208 sibling controls (112 males, 13.6 ± 2.4 years) participated in this cross-sectional study, which included anthropometry, body composition, and metabolic studies. Blunted response (BR) was defined as peak GH level &lt;7 µg/L after clonidine and arginine. Insulin sensitivity (M(lbm) ) w</pubmed_abstract><journal>Pediatric blood &amp; cancer</journal><pubmed_title>Blunted response to a growth hormone stimulation test is associated with unfavorable cardiovascular risk factor profile in childhood cancer survivors.</pubmed_title><pmcid>PMC3529966</pmcid><funding_grant_id>1UL1RR033183</funding_grant_id><funding_grant_id>M01-RR00400</funding_grant_id><funding_grant_id>RO1CA113930</funding_grant_id><funding_grant_id>M01 RR000400</funding_grant_id><funding_grant_id>UL1 TR000114</funding_grant_id><funding_grant_id>UL1 RR033183</funding_grant_id><funding_grant_id>R01 CA113930</funding_grant_id><funding_grant_id>R01CA113930</funding_grant_id><pubmed_authors>Steffen LM</pubmed_authors><pubmed_authors>Perkins JL</pubmed_authors><pubmed_authors>Petryk A</pubmed_authors><pubmed_authors>Frohnert B</pubmed_authors><pubmed_authors>Moran A</pubmed_authors><pubmed_authors>Hodges JS</pubmed_authors><pubmed_authors>Baker KS</pubmed_authors><pubmed_authors>Chow L</pubmed_authors><pubmed_authors>Zhang L</pubmed_authors><pubmed_authors>Sinaiko AR</pubmed_authors><pubmed_authors>Steinberger J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Blunted response to a growth hormone stimulation test is associated with unfavorable cardiovascular risk factor profile in childhood cancer survivors.</name><description>&lt;h4>Background&lt;/h4>Childhood cancer survivors (CCS) are at risk for growth hormone (GH) deficiency. CCS are also at increased risk for early mortality from cardiovascular (CV) disease, but the association between GH levels and CV risk remains poorly understood. The goal of this study was to examine the cross-sectional association between stimulated GH levels and CV risk factors in CCS younger than 18 years.&lt;h4>Procedure&lt;/h4>A total of 276 CCS (147 males, 14.4 ± 2.6 years) ≥5 years after cancer diagnosis, and 208 sibling controls (112 males, 13.6 ± 2.4 years) participated in this cross-sectional study, which included anthropometry, body composition, and metabolic studies. Blunted response (BR) was defined as peak GH level &lt;7 µg/L after clonidine and arginine. Insulin sensitivity (M(lbm) ) w</description><dates><release>2013-01-01T00:00:00Z</release><publication>2013 Mar</publication><modification>2025-04-05T12:54:49.469Z</modification><creation>2019-03-27T01:02:11Z</creation></dates><accession>S-EPMC3529966</accession><cross_references><pubmed>23002034</pubmed><doi>10.1002/pbc.24308</doi></cross_references></HashMap>